Updated:
Mineralys Therapeutics
Mineralys Therapeutics, led by Jon Congleton, is a public biotech targeting hypertension via aldosterone inhibition.
Mineralys Therapeutics
Mineralys Therapeutics was founded in 2019 and structured as a publicly traded biopharmaceutical company, not a traditional family office or venture fund. The firm operates from suburban Philadelphia under the leadership of CEO Jon Congleton, who previously led Juniper Pharmaceuticals through its sale to Catalent in 2018. The company raised substantial private capital — including a $40 million Series A in 2021 and a $118 million Series B led by RA Capital Management and Andera Partners in 2022 — before listing on the Nasdaq via a standard initial public offering in February 2023. The company's pipeline is built around a single lead asset, lorundrostat, a selective aldosterone synthase inhibitor being developed to treat uncontrolled and resistant hypertension. The drug targets a well-defined biological pathway distinct from the standard generic therapies used by most of the estimated 30 million Americans with uncontrolled blood pressure. Early Phase 2 data, known as the Target-HTN trial, showed a statistically significant reduction in systolic blood pressure compared to placebo, validating the mechanism and distinguishing Mineralys from broader cardiovascular conglomerates. The team is compact, centered on chief development officer Alexander Asam and a group of former Novartis and AstraZeneca hypertension specialists. The company has not disclosed a separate real estate arm, family-office structure, or philanthropic vehicle. In March 2024, Mineralys announced the completion of enrollment for its pivotal Advance-HTN Phase 3 clinical trial, positioning the firm for a potential regulatory filing in 2025, the primary operational event shaping its current posture. Mineralys departs from the typical biotech model by tackling a massive, genericized market with a targeted precision-medicine approach. Rather than pursuing a broad primary-care indication, the firm is sequencing its regulatory strategy to first capture treatment-resistant patients — a smaller, sicker population where aldosterone-driven disease is more prevalent — creating a regulatory and specialty-sales moat before expanding to front-line therapy.
General information
Firm type
Asset Manager
Year founded
2019
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Radnor
Corporate office
Radnor, PA, United States
Principals
Jon Congleton
Chief Executive Officer
Alexander Asam
Chief Development Officer
Sector focus
Frequently asked questions
What is Mineralys Therapeutics' lead drug candidate and its mechanism?
The lead candidate is lorundrostat, a highly selective aldosterone synthase inhibitor. It reduces blood pressure by directly suppressing the production of aldosterone, a hormone linked to salt retention and vascular resistance in patients whose hypertension persists despite standard therapy. Unlike mineralocorticoid receptor antagonists, it targets the synthesis pathway upstream.
How did the founder and management team originate?
CEO Jon Congleton previously served as CEO of Juniper Pharmaceuticals, a women's health company acquired by Catalent in 2018 for approximately $1.15 billion. The clinical team includes veterans of Novartis and AstraZeneca, bringing specific expertise in cardiovascular drug development and the aldosterone pathway, which is rare in the hypertension field.
What clinical validation does the lorundrostat program have?
The Target-HTN Phase 2 proof-of-concept trial met its primary endpoint, showing a statistically significant placebo-adjusted reduction in systolic blood pressure of up to 10.9 mmHg at the highest dose (per the company's publications, 2022). This result supported initiation of the pivotal 1,000-patient Advance-HTN Phase 3 trial, which completed enrollment in March 2024.
Who are Mineralys Therapeutics' key institutional investors?
The 2023 IPO was preceded by a $118 million crossover Series B financing led by RA Capital Management and Andera Partners. Catalys Pacific and Samsara BioCapital were also early significant backers. The syndicate is a mix of dedicated biotech crossover funds with cardiovascular domain experience.
How does this firm's approach differ from treating hypertension with generics?
Standard first-line hypertension therapy uses generic diuretics, ACE inhibitors, or calcium channel blockers. Mineralys is testing whether adding lorundrostat to standard background therapy can further lower blood pressure in patients who remain uncontrolled, thereby addressing a specific endocrine driver (aldosterone) that generic combinations leave untreated in a large residual population.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: